Introduction: This study describes the characteristics of the metabolic syndrome in HIV-positive patients in the Data Collection on Adverse Events of Anti-HIV Drugs study and discusses the impact of different methodological approaches on estimates of the prevalence of metabolic syndrome over time.
Methods:
We described the prevalence of the metabolic syndrome in patients under follow-up at the end of six calendar periods from 2000 to 2007. The definition that was used for the metabolic syndrome was modified to take account of the use of lipidlowering and antihypertensive medication, measurement variability and missing values, and assessed the impact of these modifications on the estimated prevalence.
Results: For all definitions considered, there was an increasing prevalence of the metabolic syndrome over time, although the prevalence estimates themselves varied widely. Using our primary definition, we found an increase in prevalence from 19.4% in 2000/2001 to 41.6% in 2006/2007 . Modification of the definition to incorporate antihypertensive and lipid-lowering medication had relatively little impact on the prevalence estimates, as did modification to allow for missing data. In contrast, modification to allow the metabolic syndrome to be reversible and to allow for measurement variability lowered prevalence estimates substantially.
Discussion: The prevalence of the metabolic syndrome in cohort studies is largely based on the use of nonstandardized measurements as they are captured in daily clinical care. As a result, bias is easily introduced, particularly when measurements are both highly variable and may be missing. We suggest that the prevalence of the metabolic syndrome in cohort studies should be based on two consecutive measurements of the laboratory components in the syndrome definition.
Introduction
The metabolic syndrome is the term used to describe a clustering of risk factors for cardiovascular disease (CVD): high triglycerides, low high-density lipoprotein (HDL), hypertension, hyperglycemia/insulin resistance and abdominal obesity [1] . The underlying premise of the metabolic syndrome requires that individuals should have at least one measurement/assessment for each of the five components; individuals are then defined as having the metabolic syndrome if at least three of the five components are present. In the general population, the prevalence of the metabolic syndrome increases with older age. In HIV infection, dyslipidaemia and alterations in glucose homeostasis are often observed, both as a consequence of exposure to antiretroviral drugs and due to dietary and lifestyle factors [2] [3] [4] . Prior studies [5] [6] [7] [8] have reported that the composition of the components making up the metabolic syndrome differs in HIV-infected individuals compared with the general population, with hypertriglyceridemia and low HDL cholesterol being predominant features in HIV metabolic syndrome. Furthermore, the metabolic syndrome has several features in common with the lipodystrophy syndrome observed in HIV-infected individuals, including insulin resistance, dyslipidaemia and fat redistribution [9] .
The application of the metabolic syndrome to an observational research setting may be complicated by the presence of missing data and/or measurement variability. Several HIV studies [5, 8, 10, [11] [12] [13] have explored the prevalence of the metabolic syndrome, very often without presenting information on how they dealt with these issues. However, both factors are likely to have an impact on the estimated prevalence of the metabolic syndrome. Therefore, the aim of this study is to explore differences in the reported prevalence of the metabolic syndrome when these factors are incorporated into statistical analyses.
Methods

Study population
The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study is a prospective, observational study formed by the collaboration of 11 cohorts following 33 347 HIV-infected individuals at 212 clinics in Europe, Australia and the United States. The primary objective of the study is to investigate the possible association between combination antiretroviral therapy (cART) and the risk of myocardial infarction (MI). The D:A:D study methodology has been described in detail elsewhere [14, 15] . Secondary objectives include the assessment of other risk factors for CVD in this population, including the metabolic syndrome [16] .
Data collection
Patients are followed prospectively during visits to outpatient clinics scheduled as a part of regular medical care. At enrolment and at least every 8 months thereafter, standardized data collection forms are completed at the sites providing information concerning family history of coronary heart disease, prior history of CVD and diabetes, cigarette smoking, blood pressure (BP), lipid-lowering and antihypertensive therapy, the presence of clinical signs of lipodystrophy and serum lipid levels (total cholesterol, HDL cholesterol, triglycerides and information on fasting conditions), as well as HIV-related information (antiviral therapy, CD4 cell counts, HIV viral loads and dates of diagnoses of all AIDS-defining diseases).
Statistical methods
We described the prevalence of the metabolic syndrome among patients under follow-up in the cohort at the end of each calendar period (2000-2001, 2002, 2003, 2004, 2005 and 2006-2007) and changes in the relative contribution of each of the metabolic syndrome components over these six periods.
Among patients who were not known to have the metabolic syndrome at study enrolment, we then described the incidence of the metabolic syndrome over time using multivariable Poisson regression models (GENMOD procedure, SAS software, version 9.1; SAS Institute Inc., Cary, North Carolina, USA). Follow-up time was counted from the date of study entry to the date when the patient first met the criteria for the metabolic syndrome, death, 1 February 2007 or 6 months after the patient's last clinic visit, whichever occurred first. As the main analyses assumed that the metabolic syndrome was irreversible, only one period of follow-up was included for each patient in these analyses. As with other analyses from the D:A:D study, to fit these models, each person's follow-up was divided into a series of consecutive 1-month periods, and a patient's covariate data were updated at the start of each month.
Definition of the metabolic syndrome
For our main analyses (definition 1), we considered a modified National Cholesterol Education Program (NCEP) definition of the metabolic syndrome [1], which incorporates five criteria: triglycerides of at least 1.7 mmol/l, HDL of 1.0 mmol/l or less in men and of 1.3 mmol/l or less in women, hypertension (SBP >130 mmHg or DBP >85 mmHg), BMI of more than 30 kg/m 2 as a surrogate for waist circumference and a diagnosis of diabetes mellitus replacing fasting glucose. A patient was defined as having the metabolic syndrome on the first date when at least three of the five components were present. As these data were collected as a part of routine medical care, information on some components of the metabolic syndrome may have been missing at times; for the purposes of our main analyses, where information was missing for an individual on any component of the definition, that component was assumed to be absent. Furthermore, for these main analyses, the various components of the metabolic syndrome were assumed to be irreversible; thus, once an individual had met one of the five criteria, it was assumed that the individual would always meet those criteria.
We then compared the results from the analysis using definition 1 with those obtained when the definition was modified to deal with missing data and/or measurement variability. In particular, we considered the following modifications to the definition. First, the use of lipidlowering therapy (LLT) was treated as an equivalent criterion to triglycerides or HDL in the definition, with the restriction that each patient could meet a maximum of two lipid criteria (i.e. if a patient met the triglycerides, HDL and LLT criteria, then the patient would still only be considered as meeting two of the five metabolic syndrome criteria). Similarly, the use of antihypertensive medication was treated as an equivalent criterion to high SBP or DBP when assessing the criteria for hypertension (definition 2). Second, we explored the effect of missing data on our conclusions, by only including follow-up that occurred while a patient had complete information on at least three of the five metabolic syndrome components (definition 3). Third, our analyses of trends over time were repeated after assuming that the lipid and hypertension components of the metabolic syndrome could be reversible; thus, if a patient experienced a drop in triglycerides or BP below the threshold, or an increase in HDL above the threshold, irrespective of the cause, they no longer met those criteria (definition 4). Fourth, we modified the definition of the metabolic syndrome further to ensure that all measurements (triglycerides, HDL cholesterol or BP) had been done in the previous year; if a patient did not have a measurement within any 1-year period, this information was assumed to be missing until a new measurement became available (the requirement that patients had information on at least three of the five components was also applied here, definition 5). Fifth, as the laboratory components of the metabolic syndrome may be subject to considerable measurement variability, we re-ran our main analyses (irreversible metabolic syndrome, missing ¼ absent) after requiring that at least two consecutive measurements were required to be above (or below) each threshold before that criterion was met (definition 6).
Results
The prevalence of the metabolic syndrome at entry in the Data Collection on Adverse Events of Anti-HIV Drugs study The main characteristics of the 33 347 individuals included in the D:A:D study and the components of the metabolic syndrome that were present at study entry are shown in Table 1 . At study entry, 15 759 (47.3%) individuals were known to have high triglycerides, 10 038 (30.1%) had low HDL cholesterol, 5291 (15.9%) had hypertension, 1705 (5.1%) had high BMI and 952 (2.9%) had a diagnosis of diabetes mellitus. Overall, 2439 (7.3%) individuals met the criteria for the metabolic syndrome at study entry. Of the 33 347 patients in the study, 523 (1.6%) had already experienced a cardiovascular event prior to study entry. Model assuming that MS is irreversible, and where information on components of the MS is missing, then these components are absent. natural variability of some of these measurements (lipids were often measured in nonfasting conditions) and the impact of the increasing use of LLT and antihypertensive medication and potentially the switching of antiretrovirals. Overall, the relative importance of each component of the metabolic syndrome remained similar for all definitions (data not shown), although the nonlaboratory components of the metabolic syndrome (i.e. diabetes mellitus and BMI) were relatively more frequent when using definitions that allowed the laboratory components of the metabolic syndrome to be reversible.
Discussion
Reports of the metabolic syndrome amongst HIVinfected individuals have been relatively small and of cross-sectional design [6, 7, 10, 12] . Large differences in prevalence of the metabolic syndrome in HIV-infected individuals have been published. Our findings are similar to other European estimates in patients of similar age [8, 11, 12] . Until now, studies have compared the different established definitions of the metabolic syndrome, often focusing on the definitions proposed by the NCEP and the International Diabetes Federation (IDF). These studies have reported that more patients were identified with the metabolic syndrome when the NCEP definition was used [6, 17] . However, it is well known that observational datasets may often be affected by missing data and several components of the metabolic syndrome are based on laboratory measurements that are known to exhibit variability. It is likely that currently published studies differ in the way in which the definitions of the metabolic syndrome are applied in the presence of missing and/or variable data, but to our knowledge, the impact of these factors on the reported prevalence of the metabolic syndrome has not been described. Finally, there is no consensus about the way in which lipid-lowering and/or antihypertensive medications should be incorporated into definitions of the metabolic syndrome.
The D:A:D study has the strength of including more than 33 000 patients and is the largest study to date which has prospectively collected information on CVD risk factors in HIV-infected individuals. However, in common with all observational studies, the collection of data may be limited by missing data. Furthermore, as lipid and BP measurements are collected as a part of routine clinical care, there may be many sources of variation in these markers. By using different analytical approaches in this study, we identified several methodological challenges in our attempt to evaluate the change in prevalence of the metabolic syndrome over time.
Although our main analysis showed a considerable rate of progression of metabolic syndrome over the 6 years from 19.4 to 41.6%, this increase could represent a combination of aging of the cohort: an increased awareness, in general (and in this cohort, in particular), towards increased monitoring of dyslipidaemia and of hypertension, that is, persons are now better screened for the components of the metabolic syndrome. However, other factors also need to be taken into account.
Although our main analyses have applied the definition of the metabolic syndrome that is in current use, in clinical practice, it is unlikely that a diagnosis of the metabolic syndrome would be based on a single abnormal laboratory measurement only (an abnormal measurement would most often be followed by a confirmatory measurement), and likewise, a diagnosis of diabetes mellitus would also be based on repeated measurements of fasting glucose. By requiring this more 'strict' definition of the metabolic syndrome -and thereby allowing for some of the known biological variation within lipids -we required (using definition 6) that the metabolic syndrome definition could only be fulfilled if an individual had two consecutive laboratory values above or below each threshold. In doing this, we increased the likelihood that each laboratory measurement was really abnormal and reduced the chance that a patient had met a particular metabolic syndrome criterion simply following an on-off high (or low) measurement for that value. As a result, the apparent prevalence of the metabolic syndrome was half of that reported in our main analysis. A similar effect was noticed when we allowed the components of the metabolic syndrome to be reversible (definition 4). With this approach, there was almost no increase in prevalence throughout the study period. This probably reflects the fact that many high-risk patients started LLT, and as a result, their lipids were reduced to a level such that they no longer met the criteria for the metabolic syndrome.
Because of the increasing use of LLT and antihypertensive drugs amongst HIV-infected individuals [12, 18] , and a recent update of the NCEP III guidelines from the American Heart Association [19] , we also repeated the analyses after modifying our definition of the metabolic syndrome to allow for the use of these drugs (definition 2). In particular, following recommendations by Gotto et al. [20] , the use of LLT was treated as an equivalent criterion to triglycerides or HDL, and the use of antihypertensive medication was treated as an equivalent criterion to high SBP or DBP when assessing the criteria for hypertension. As suspected, this approach led to an increase in metabolic syndrome prevalence throughout the study period, that is, an increase of around 2.5% in each year compared with the main analysis, resulting in our highest estimates of the prevalence. One study from the background population has included LLT in a similar manner: among patients with established CVD, an additional 7% were identified with the metabolic syndrome when including LLT use in the definition [21] [22] [23] .
Limitations By using diabetes mellitus diagnosed under prospective follow-up instead of fasting glucose values, we get a rather conservative estimate of the prevalence and might underestimate the prevalence of the metabolic syndrome as well as the contribution of diabetes mellitus to the risk of the metabolic syndrome. Others have shown a much higher prevalence of impaired fasting glucose of above 20% [12] . As the D:A:D study does not collect waist circumference, we used increased BMI in place of this component of the metabolic syndrome, as in other studies [24] . The use of BMI may have resulted in lower estimated effects compared with waist circumference because BMI includes total fat mass. Furthermore, the lipodystrophic changes with central fat accumulation and loss of peripheral subcutaneous fat may underestimate the prevalence of the metabolic syndrome, as these patients might have a normal BMI and might not be sufficiently captured by our modified NCEP definition. Our information on the fasting conditions for the measurements of lipids were available in only around 60% of patients, and as a result, we may have overestimated the contribution of these components.
Conclusion
Our main analysis, assuming that the metabolic syndrome is irreversible, suggested an increasing prevalence of the metabolic syndrome in the D:A:D study from 19.4% in 2000 to 41.6% in 2006/7. However, other suggested definitions did not confirm the dramatic increase in prevalence over time. We believe that some of this increase is most likely an artifact representing a combination of aging of the cohort and an increased awareness towards screening for the components of the metabolic syndrome. Additionally, it is questionable whether the underlying assumption of the metabolic syndrome on the basis of one single measurement being irreversible is correct [25] . For the assessment of the metabolic syndrome in observational cohort studies, we would recommend that the definition of the metabolic syndrome requires that at least two consecutive measurements of each of the laboratory components are abnormal before the individual is allowed to meet that criterion.
